Normalization of Hemoglobin in Patients With CKD May Cause Harm: But What Is the Mechanism?

American Journal of Kidney Diseases

Volumn 52, Issue 4, 2008, Pages 642-644

  Littlewood, T J ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECT; EDITORIAL; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INFLAMMATION; MORTALITY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS;

ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; RENAL DIALYSIS; THROMBOCYTOSIS;

EID: 52049107098     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.07.001     Document Type: Editorial

References (25)

1. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736
2. Winearls C., Oliver D.O., Pippard M.J., et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2 (1986) 1175-1178
3. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300 (1990) 573-578
4. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter trial. Ann Intern Med 111 (1989) 992-1000
5. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
6. Drueke T.B., Locatelli F., Clyne N., et al. Normalisation of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
7. Singh A.K., Szczech L., Tang K.L., et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
8. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
9. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
10. Hedenus M., Adriansson M., SanMiguel J., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
11. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
12. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first line chemotherapy: A survival study. J Clin Oncol 23 (2005) 5960-5972
13. Nowrousian M.R., Dunst J., and Vaupel P. Erythropoiesis-stimulating agents: Favourable safety profile when used as indicated. Stralenther Onkol 3 (2008) 121-136
14. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in haemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
15. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 10 (2004) 225-232
16. Tang W.W., Stead R.A., and Goodkin D.A. Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18 (1998) 262-273
17. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141 (2008) 14-31
18. Lu C.C., Chang K.W., Chou F.C., Cheng C.Y., and Liu C.J. Association of pre-treatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol 43 (2007) 283-288
19. Bensalah K., Leray E., Fergelot P., et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175 (2006) 859-863
20. Henry D.H., Dahl N.V., and Auerbach M. Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis?. Blood (ASH Annual Meeting Abstracts) (2007) 1625 (abstr)
21. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Beckie M., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
22. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
23. Auerbach M., Ballard H., Trout J.R., et al. Intravenous iron optimises the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
24. Henry D.H., Dahl N.V., Auerbach M., Tchekmedyian S., and Laufman L.R. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12 (2007) 231-242
25. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron With Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984